Purdue Pharma partners with Alivio Therapeutics to advance ALV-107 in interstitial cystitis or bladder pain syndrome.
Global Banking News-January 28, 2019-Purdue Pharma partners with Alivio Therapeutics to advance ALV-107 in interstitial cystitis or bladder pain syndrome
(C)2019 ENPublishing - http://www.enpublishing.co.uk
Prescription medicines company Purdue Pharma LP revealed on Monday the launch of a partnership to advance the ALV-107 product candidate through clinical development from Alivio Therapeutics.
ALV-107 is a non-opioid treatment being developed for interstitial cystitis/bladder pain syndrome (IC/BPS). The ALV-107 programme received a USD3.3m US Department of Defense (DoD) Technology/Therapeutic Development Award to support Alivio's preclinical research and development activities.
Under the partnership, Purdue will exercise the option to collaborate on a limited number of additional compounds utilizing Alivio's inflammation-targeting
In conjunction with the agreement, Alivio will receive up to USD14.75m in upfront and near-term license exercise payments and is eligible to receive royalties on product sales and over USD260m in research and development milestones. Purdue has an option to invest in Alivio's next equity financing.
Additionally, Alivio's platform technology has demonstrated proof-of-concept in ten different preclinical models of inflammation including a validated preclinical model for the treatment of IC/BPS. ALV-107 relieved pain at all study time points post therapy.
Interstitial Cystitis or Bladder Pain Syndrome (IC/BPS) is a chronic bladder condition that consists of discomfort or pain in the bladder or surrounding pelvic region and is often associated with frequent urination. It is estimated to affect up to 12m people in the US and is more common in women than men.
((Distributed via M2 Communications - http://www.m2.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||Global Banking News (GBN)|
|Date:||Jan 28, 2019|
|Previous Article:||Colgate posts higher net income of USD606m for Q4 2018.|
|Next Article:||AMPLEXOR signs translation agreement with DG CONNECT in Europe.|